Core Viewpoint - Predictive Oncology Inc. has announced a registered direct offering of 363,336 shares of common stock at a price of $1.50 per share, aiming to raise approximately $545,004 before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about February 19, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. - The net proceeds from the offering will be used for working capital and general corporate purposes [2]. Group 2: Regulatory Information - The shares are being offered under a "shelf" registration statement on Form S-3, which was declared effective by the SEC on May 21, 2024 [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC [3]. Group 3: Company Overview - Predictive Oncology is focused on AI-driven drug discovery and biologics, utilizing its AI platform, PEDAL, which predicts with 92% accuracy the response of tumor samples to drug compounds [5]. - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [5]. - Predictive Oncology is headquartered in Pittsburgh, PA [5].

Core Viewpoint - Predictive Oncology Inc. has successfully identified several abandoned or discontinued drugs for further testing and development, particularly in ovarian and other cancer types, creating significant business development opportunities with large pharmaceutical companies [1][6]. Group 1: Drug Repurposing Initiative - The company has developed a registry of promising drug candidates that can potentially be repurposed for additional or alternative indications using publicly available datasets [2]. - By leveraging its proprietary AI and machine learning platform, along with a vast biobank of primary tumor samples, Predictive has identified drug candidates with promising mechanisms of action for clinical testing, focusing initially on ovarian, colon, and breast cancer [3][5]. - Early results from the AI platform indicate that it can predict an additional 10 times the number of measured experiments, significantly reducing the time required for wet lab testing and identifying two drugs that outperformed a known standard of care for colon cancer [4]. Group 2: Market Potential and Growth - The market for repurposed drugs is projected to grow from $32.1 billion in 2023 to $51.8 billion by 2033, representing a compound annual growth rate (CAGR) of 4.5% [6]. - The company believes that repurposing approved or abandoned drugs for additional indications offers a meaningful opportunity to develop new therapies faster and at a lower cost compared to traditional drug discovery methods [6]. Group 3: Technological Capabilities - Predictive Oncology's AI platform, PEDAL, has a prediction accuracy of 92% regarding tumor response to specific drug compounds, enhancing the selection process for drug/tumor type combinations for further testing [8]. - The company possesses a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing one of the industry's broadest AI-based drug discovery solutions [8].

Core Insights - Predictive Oncology Inc. announced positive results from a study in collaboration with Tecan, presented at the 2025 SLAS International Conference, focusing on the use of patient-derived tumor spheroids for drug discovery [1][4] Group 1: Company Overview - Predictive Oncology is a leader in AI-driven drug discovery and biologics, utilizing a vast biobank of cryopreserved live cell tumor specimens [1][9] - The company’s AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to specific drug compounds, enhancing drug selection processes [9] - Tecan, a partner in the study, is a global leader in laboratory automation, with 2023 sales of CHF 1,074 million (approximately USD 1,194 million) [7] Group 2: Research and Development - The study utilized patient-derived tumor models (PDTMs) to develop personalized therapies, addressing challenges in accessibility and scalability of primary tumor cells through cryopreserved dissociated tumor cells (DTCs) [2][5] - Optimized growth conditions and drug treatment protocols were established for tumor models derived from cryopreserved DTCs, demonstrating that 3D models are more representative of in vivo conditions compared to 2D models [3] - The research highlights the importance of monitoring tumor growth and drug response through advanced imaging techniques and automated analysis [6] Group 3: Market Insights - The high throughput screening (HTS) market is projected to reach $69.5 billion by 2032, with a compound annual growth rate (CAGR) of 12.18%, driven by the adoption of 3D cell cultures and organoids [4]

Core Insights - Predictive Oncology Inc. plans to launch its ChemoFx® drug response assay in Europe, focusing on gynecological cancers, particularly ovarian cancer, while expanding its availability in the United States [1][3] - The ChemoFx® assay quantifies individual cancer patients' tumor responses to various chemotherapeutic agents, aiding in personalized treatment selection [2][4] - The company has a biobank of approximately 150,000 live cell tumor samples, with nearly half being gynecological cancers, which supports its AI-driven drug discovery platform [4][6] Company Overview - Predictive Oncology utilizes AI and machine learning to enhance biomarker and drug discovery, achieving a 92% accuracy rate in predicting tumor responses to drug compounds [6] - The ChemoFx® assay previously generated over $25 million in annual gross revenues when first introduced to the market, indicating its potential for significant revenue generation [5] - The company is headquartered in Pittsburgh, PA, and operates a CLIA laboratory to support its drug discovery solutions [6]

Core Insights - Renovaro Inc. has entered into a binding Letter of Intent (LOI) to acquire Predictive Oncology in an all-stock transaction, which will enhance its capabilities in cancer diagnostics and therapeutics powered by artificial intelligence [1][2] Short-Term Synergies - The acquisition provides access to a biobank of over 150,000 tumor specimens and 200,000 pathology slides, which will accelerate biomarker discovery and clinical trial optimization [6] - Predictive Oncology's AI/ML platform has a proven accuracy of 92% in predicting tumor-drug responses, which will support oncologists in making informed treatment decisions [2][8] - The combined organization will streamline the development and rollout of new diagnostic tests in Europe, improving speed to market and expanding global reach [6] Long-Term Vision - The integration of Predictive Oncology's drug discovery platform with Renovaro's liquid biopsy approach aims to create a comprehensive solution for cancer diagnostics and personalized therapies [6] - The partnership is expected to advance cancer therapy at every stage of the patient's journey, improving outcomes and reducing costs [6] - The acquisition will enable collaboration across multi-omic platforms for drug discovery, enhancing the overall capabilities of the combined entity [6] Transaction Details - Renovaro will acquire 100% of Predictive Oncology's common shares through the issuance of Preferred stock [7]

- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders' interest, augment business development opportunities and positioning in the capital markets - PITTSBURGH, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today announced that it has entered into a binding letter of intent with Renovaro, Inc. (NASDAQ: ...

PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction. The transaction is expected to close on or about July 26, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transaction, coupled with an additional $3.58 million in net proceeds raised in May 2024 through the Company's at-the-market facility, for working capital and other general corporate purposes. This press release does not constitute an offer to sell or ...

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common ...

GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis. It is estimated that drugs targeting GPCRs represent more than 30% of the global market for therapeutic drugs, yet the number of characterized GPCR targets represent just a small fraction of the GPCR superfamily, suggesting significant potential to further target GPCRs for future drug discovery and development2,3. "As ...